- Home
- BFRG vs KZIA Comparison
BFRG vs KZIA Comparison
Compare BFRG & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRG
- KZIA
- Stock Information
- Founded
- BFRG 2017
- KZIA 1994
- Country
- BFRG United States
- KZIA Australia
- Employees
- BFRG N/A
- KZIA N/A
- Industry
- BFRG Retail: Computer Software & Peripheral Equipment
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- BFRG Technology
- KZIA Health Care
- Exchange
- BFRG Nasdaq
- KZIA Nasdaq
- Market Cap
- BFRG 21.2M
- KZIA 18.7M
- IPO Year
- BFRG 2023
- KZIA 1999
- Fundamental
- Price
- BFRG $2.04
- KZIA $3.08
- Analyst Decision
- BFRG
- KZIA Strong Buy
- Analyst Count
- BFRG 0
- KZIA 1
- Target Price
- BFRG N/A
- KZIA $20.00
- AVG Volume (30 Days)
- BFRG 201.5K
- KZIA 85.9K
- Earning Date
- BFRG 11-08-2024
- KZIA 01-03-2025
- Dividend Yield
- BFRG N/A
- KZIA N/A
- EPS Growth
- BFRG N/A
- KZIA N/A
- EPS
- BFRG N/A
- KZIA N/A
- Revenue
- BFRG N/A
- KZIA $1,655,324.00
- Revenue This Year
- BFRG N/A
- KZIA $806.89
- Revenue Next Year
- BFRG N/A
- KZIA N/A
- P/E Ratio
- BFRG N/A
- KZIA N/A
- Revenue Growth
- BFRG 550.00
- KZIA 248000.00
- 52 Week Low
- BFRG $1.43
- KZIA $1.90
- 52 Week High
- BFRG $8.35
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- BFRG 41.32
- KZIA 30.94
- Support Level
- BFRG $2.11
- KZIA $2.78
- Resistance Level
- BFRG $2.77
- KZIA $4.20
- Average True Range (ATR)
- BFRG 0.29
- KZIA 0.55
- MACD
- BFRG -0.03
- KZIA -0.13
- Stochastic Oscillator
- BFRG 7.32
- KZIA 9.92
About BFRG Bullfrog AI Holdings Inc.
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.